Logotype for Jubilant Pharmova Limited

Jubilant Pharmova (530019) Q1 26/27 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Jubilant Pharmova Limited

Q1 26/27 earnings summary

16 Nov, 2026

Executive summary

  • Q1'FY27 revenue was ₹22,211 million (Rs. 2,229 Cr.), up 17% YoY; EBITDA was Rs. 268 Cr., down 11%, and consolidated profit was ₹564 million, down 45%.

  • Growth was led by CDMO sterile injectables and Radiopharma; lower SPECT availability and Montreal remediation costs weighed on profitability.

  • Vision 2030 targets revenue at 2x FY24 levels, 23%–25% EBITDA margin, zero net debt and high-teens ROCE.

Financial highlights

  • Revenue from operations was ₹22,211 million, versus ₹18,789 million in Q1 FY26 and ₹22,722 million in Q4 FY26; total income was Rs. 2,249 Cr., up 18% YoY.

  • Consolidated profit was ₹564 million, versus ₹1,025 million in Q1 FY26 and ₹1,193 million in Q4 FY26; basic EPS was ₹3.57, versus ₹6.49 and ₹7.55, respectively.

  • Standalone revenue was ₹671 million, versus ₹595 million in Q1 FY26 and ₹703 million in Q4 FY26; standalone profit was ₹74 million, versus ₹57 million and ₹571 million, respectively.

  • EBITDA was Rs. 268 Cr., down 11% YoY; margin contracted 385 bps to 11.9%. Reported and normalized PAT were Rs. 56 Cr., down 45%, with reported PAT margin at 2.5%.

  • Unaudited standalone and consolidated results for the quarter ended June 30, 2026, were approved by the Board and prepared under Ind AS and SEBI regulations.

Outlook and guidance

  • Vision 2030 targets revenue of Rs. 13,500 Cr. and EBITDA margin of 23%–25%, versus TTM revenue of Rs. 8,608 Cr. and margin of 15%.

  • Radiopharma targets revenue above 2x FY24 by FY30; margins are expected to improve after H2'FY27 as Montreal supply normalizes, with new products launching from FY28.

  • Six PET sites are planned to expand the network from 3 to 9, with full operation by FY28; existing-site expansion is also expected to support growth.

  • CDMO sterile injectables targets more than 2x FY24 revenue and margin above 25% by FY30; Line 3 and Line 4 are scaling, with Montreal Line 5 technology-transfer revenue expected from FY29.

  • Drug Discovery Services targets ~3x FY24 revenue by FY30; Generics targets ~2x FY24 revenue and 15%–17% margin, while API targets 2x FY24 revenue and margin above 15%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Jubilant Pharmova